124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Clinical trials / Disease details
Clinical trials : 12 / Drugs : 14 - (DrugBank : 5) / Drug target genes : 6 - Drug target pathways : 23
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04658823 (ClinicalTrials.gov) | December 10, 2020 | 29/11/2020 | Efficacy and Safety of Tocotrienols in CADASIL | A Randomized Placebo-controlled Double-blind Pilot / Phase II Study to Assess the Efficacy and Safety of HOV-12020 in Patients With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) | Cadasil | Drug: HOV-12020 (Palm tocotrienols complex);Drug: Placebo | Hovid Berhad | NULL | Not yet recruiting | 45 Years | 75 Years | All | 50 | Phase 2 | France |